Jim Simons’s Dyne Therapeutics DYN Stock Holding History

Jim Simons’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.01M	Sell	360,572 -173,028	-32%	-$3.22M	0.01%	1178
2026 Q1	$9.7M	Buy	533,600 +62,955	+13%	+$1.09M	0.02%	985
2025 Q4	$9.21M	Buy	470,645 +125,145	+36%	+$2.37M	0.01%	958
2025 Q3	$4.37M	Buy	+345,500	New	+$3.94M	0.01%	1580
2024 Q3	–	Sell	-126,000	Closed	-$4.45M	–	3609
2024 Q2	$4.45M	Buy	+126,000	New	+$3.66M	0.01%	1378
2023 Q2	–	Sell	-73,300	Closed	-$844K	–	4005
2023 Q1	$844K	Sell	73,300 -34,400	-32%	-$447K	﹤0.01%	2584
2022 Q4	$1.25M	Buy	107,700 +2,800	+3%	+$32.4K	﹤0.01%	2397
2022 Q3	$1.33M	Buy	104,900 +13,700	+15%	+$157K	﹤0.01%	2315
2022 Q2	$627K	Buy	91,200 +48,500	+114%	+$334K	﹤0.01%	3017
2022 Q1	$412K	Sell	42,700 -25,800	-38%	-$220K	﹤0.01%	3302
2021 Q4	$814K	Sell	68,500 -72,000	-51%	-$1.01M	﹤0.01%	2798
2021 Q3	$2.28M	Buy	+140,500	New	+$2.49M	﹤0.01%	1986

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jim Simons's DYN Position: Q2 2026 in Review

Jim Simons reduced its Dyne Therapeutics (DYN) stake by 32% in Q2 2026, selling an estimated $3.22M and leaving 360,572 shares worth $8.01M. The position accounts for 0.01% of the portfolio, ranked #1178.

Jim Simons first reported a position in DYN in Q3 2021 and has held it in 12 quarters since. The position peaked at $9.7M in Q1 2026. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

Jim Simons held 360,572 shares of Dyne Therapeutics worth $8.01M as of Q2 2026.
Jim Simons sold 173,028 Dyne Therapeutics shares in Q2 2026, an estimated $3.22M.
Dyne Therapeutics made up 0.01% of Jim Simons's portfolio in Q2 2026, its #1178 holding.
Jim Simons first reported a position in Dyne Therapeutics in Q3 2021 and has held it in 12 quarters since.
Jim Simons's Dyne Therapeutics position peaked at $9.7M in Q1 2026.
245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.